Skip to content
Menu

Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26

Benzinga Newsdesk 4 weeks ago

Stock SplitNews

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,

Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that its Board of Directors, approved a 1-for-10 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share ("Reverse Stock Split"). The Reverse Stock Split is anticipated to be effective as of the open of the market October 26, 2026.

Read at benzinga.com

← All stock news